Esco Aster, a cell and derivatives contract research, development, and manufacturing organisation (CRDMO) based in Singapore, has signed a clinical cGMP manufacturing contract with Shine-On Biomedical. The collaboration focuses on Shine-On’s innovative HLA-G targeting exosome drug delivery platform, which aims to enhance drug delivery efficiency. This partnership follows Shine-On’s sponsorship of Esco Aster in 2023 for cGMP services, which included high-yield exosome development using Esco Aster’s cell line platform.
The partnership is significant as it supports Shine-On’s Investigational New Drug (IND) submission, which was cleared by the US Food and Drug Administration (FDA) in Q1 2025. Esco Aster’s comprehensive technical reports on process, analytical, and formulation development, as well as exosome drug loading and stability studies, were crucial in this approval process.
Esco Aster is also providing technical services for exploratory exosome loading feasibility studies, as instructed by Shine-On Biomedical. Shine-On is recognised as an emerging innovator in the field of exosome-based drug delivery, and this collaboration is expected to advance their proprietary product development.
This partnership highlights the growing importance of exosome technology in drug delivery systems, potentially leading to more effective treatments. The collaboration between Esco Aster and Shine-On Biomedical could pave the way for future innovations in the pharmaceutical industry, enhancing the delivery and efficacy of therapeutic agents.
